cmv

CMV pp65(13-27) is a bioactive peptide derived from the 65k lower matrix phosphoprotein of the human cytomegalovirus, specifically comprising amino acid residues 13 to 27. It includes a nine-amino-acid sequence (LGPISGHVL) that corresponds to the consensus binding motif for the major histocompatibility complex H2-Dd T-cell epitope.

LCMV gp33-41 acetate is a sequence of lymphocytic choriomeningitis virus which restricted by major histocompatibility complex class I H-2Db and presented to cytotoxic T lymphocytes.

LCMV gp33-41, the carboxyl-extended 11-aa-long peptide, is an lymphocytic choriomeningitis virus sequence restricted by MHC class I H-2Db molecules and presented to cytotoxic T lymphocytes.This is the H-2Db restricted epitope derived from the lymphocytic

LCMV gp33-41 (TFA), an 11-amino-acid carboxyl-extended peptide, comprises a lymphocytic choriomeningitis virus sequence that is presented by MHC class I H-2Db molecules to cytotoxic T lymphocytes [1].

LCMV gp33-41 (TFA), the carboxyl-extended 11-aa-long peptide, is an lymphocytic choriomeningitis virus sequence restricted by MHC class I H-2Db molecules and presented to cytotoxic T lymphocytes[1].

LCMV GP (61-80) is a peptide fragment derived from LCMV glycoprotein (GP) and corresponds to amino acids 61-80. This specific epitope, LCMV GP (61-80), has the ability to elicit CD4+ T-cell response.